Skip to main content
SpringerLink
Log in

Correlation Between Survival and Number of Mobilized CD34+ Cells in Patients with Multiple Myeloma or Waldenström Macroglobulinemia

  • Published:
Pathology & Oncology Research

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation is the established treatment for symptomatic multiple myeloma (MM) or Waldenström macroglobulinemia (WM). We retrospectively analyzed the impact of mobilized CD34+ cell number on clinical outcomes in patients with MM or WM who underwent autologous stem cell transplantation in our hospital from 1997 to 2007. A total of 39 patients were identified. All patients received peripheral stem cell support after a conditioning regimen. We defined patients with collection of a large number (≥ 8 × 106/kg) of CD34+ cells as super mobilizers (SM), and all others as normal mobilizers (NM). Although hematological engraftment was earlier in the SM group, overall survival did not differ significantly between groups (P = 0.392). Likewise, no significant differences were seen in progression-free survival (P = 0.201) or survival after relapse (P = 0.330). In conclusion, our retrospective study could not find any correlation between survival and number of mobilized CD34+ cells, in contrast to previously reported results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole DH et al (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789–793

    CAS  PubMed  Google Scholar 

  3. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

    Article  CAS  PubMed  Google Scholar 

  4. Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233

    Article  CAS  PubMed  Google Scholar 

  5. Stockerl-Goldstein KE, Reddy SA, Horning SF et al (2000) Favorable treatment outcome in non-Hodgkin’s lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 6:506–512

    Article  CAS  PubMed  Google Scholar 

  6. Hiwase DK, Hiwase S, Bailey M et al (2008) Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 14:116–124

    Article  PubMed  Google Scholar 

  7. Bolwell BJ, Pohlman B, Rybicki L et al (2007) Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 40:437–441

    Article  CAS  PubMed  Google Scholar 

  8. Wang S, Nademanee A, Qian D et al (2007) Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 47:2207–2216

    Article  PubMed  Google Scholar 

  9. Galimberti S, Morabito F, Guerrini F et al (2003) Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 120:405–412

    Article  PubMed  Google Scholar 

  10. Gordan LN, Sugrue MW, Lynch JW et al (2003) Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 44:815–820

    Article  CAS  PubMed  Google Scholar 

  11. O’Shea D, Giles C, Terpos E et al (2006) Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 37:731–737

    Article  PubMed  Google Scholar 

  12. Krejci M, Buchler T, Hajek R et al (2005) Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 35:159–164

    Article  CAS  PubMed  Google Scholar 

  13. Wahlin A, Eriksson M, Hultdin M (2004) Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol 73:263–268

    Article  PubMed  Google Scholar 

  14. Krejci M, Hajek R, Buchler T et al (2007) Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients. Neoplasma 54:143–148

    CAS  PubMed  Google Scholar 

  15. Dean R, Masci P, Pohlman B et al (2005) Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant 36:1049–1052

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by a grant for clinical cancer research from the Ministry of Health, Labor and Welfare of Japan. We would like to thank the staff of the Hematology Division at Tokyo Metropolitan Cancer and the Infectious Diseases Center, Komagome Hospital, for their excellent patient care.

Author information

Authors and Affiliations

  1. Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan

    Kazuhiko Kakihana, Kazuteru Ohashi, Hideki Akiyama & Hisashi Sakamaki

Authors
  1. Kazuhiko Kakihana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuteru Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideki Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisashi Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuteru Ohashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kakihana, K., Ohashi, K., Akiyama, H. et al. Correlation Between Survival and Number of Mobilized CD34+ Cells in Patients with Multiple Myeloma or Waldenström Macroglobulinemia. Pathol. Oncol. Res. 16, 583–587 (2010). https://doi.org/10.1007/s12253-009-9238-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-009-9238-x

Keywords

Search

Navigation